000 01526 a2200445 4500
005 20250517165259.0
264 0 _c20170922
008 201709s 0 0 eng d
022 _a1744-764X
024 7 _a10.1080/14740338.2017.1354986
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aJiang, Nan
245 0 0 _aRisk of gastrointestinal complications in breast cancer patients treated with neratinib: a meta-analysis.
_h[electronic resource]
260 _bExpert opinion on drug safety
_cOct 2017
300 _a1111-1119 p.
_bdigital
500 _aPublication Type: Journal Article; Meta-Analysis
650 0 4 _aAntineoplastic Agents
_xadministration & dosage
650 0 4 _aBreast Neoplasms
_xdrug therapy
650 0 4 _aDiarrhea
_xchemically induced
650 0 4 _aFemale
650 0 4 _aGastrointestinal Diseases
_xchemically induced
650 0 4 _aHumans
650 0 4 _aNausea
_xchemically induced
650 0 4 _aQuinolines
_xadministration & dosage
650 0 4 _aRisk
650 0 4 _aVomiting
_xchemically induced
700 1 _aSong, Xiang-Wei
700 1 _aLin, Jing-Jing
700 1 _aWang, Zhan-Yu
700 1 _aZhang, Bei-Ning
700 1 _aLi, Ao
700 1 _aYan, Ru-Yi
700 1 _aYan, Hong-Feng
700 1 _aFu, Xiao-Yan
700 1 _aZhou, Jin-Lian
700 1 _aLi, Cheng-Lin
700 1 _aCui, Yan
773 0 _tExpert opinion on drug safety
_gvol. 16
_gno. 10
_gp. 1111-1119
856 4 0 _uhttps://doi.org/10.1080/14740338.2017.1354986
_zAvailable from publisher's website
999 _c27424717
_d27424717